Peptide receptor radionuclide therapy in patients with medullary thyroid carcinoma: predictors and pitfalls

BACKGROUND: For progressive metastatic medullary thyroid carcinoma (MTC), the available treatment options with tyrosine kinase inhibitors result in grade 3–4 adverse events in a large number of patients. Peptide Receptor Radionuclide Therapy (PRRT), which has also been suggested to be a useful treat...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:BMC Cancer
Egile Nagusiak: Beukhof, Carolien M., Brabander, Tessa, van Nederveen, Francien H., van Velthuysen, Marie-Louise F., de Rijke, Yolanda B., Hofland, Leo J., Franssen, Gaston J. H., Fröberg, Lideke A. C., Kam, Boen L. R., Visser, W. Edward, de Herder, Wouter W., Peeters, Robin P.
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: BioMed Central 2019
Gaiak:
Research Article
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC6451300/
https://ncbi.nlm.nih.gov/pubmed/30953466
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12885-019-5540-5
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak